Skip to main content
S&P 5007,688.87+1.58%DOW53,357.19+3.03%NASDAQ25,736.51+1.44%BTC$80,046.00+2.82%ETH$2,416.05+5.56%GOLD$4,069.10+3.27%OIL$88.67-7.72%
Smart Investors Daily
SID Premium
CH

OTC · CHGCY

Chugai Pharmaceutical Co., Ltd.

Healthcare · Drug Manufacturers - General

$22.11

Up+$0.59 (+2.74%)

Updated Nov 4, 2026, 9:04 PM

SID Score

6.1/10

Composite research score

Smart Money

46/100

Neutral

Market cap
89.03B
P/E ratio
35.25
Dividend yield
2.78%
52-week range
— – —
Volume
13.91K
Avg. volume
145.36K

Price performance · CHGCY

CHGCY price history

1M range · 0 trading sessions · Daily adjusted prices

CHGCY does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest CHGCY news

The latest Smart Investors Daily articles mentioning CHGCY.

Stock researchCompany · Overview

CHGCY research

Overview

Company profile and research snapshot.

Company profile

CHUGAI PHARM UNSP/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
—
Implied upside
—
Analysts
20
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 29, 2026

Chugai Pharmaceutical (TSE:4519) Stock Price Trails Strong Q3 Earnings

Chugai Pharmaceutical entered Q3 2026 earnings with a solid recent run, the stock up about 3.9% over the past month but still lower over 90 days. Investors had been treating it as a high quality growth story with a premium P/E and rich pipeline. The fresh numbers landed with real weight. Q3 revenue was ¥404,743m and basic earnings per share were ¥87.25, both higher than the prior quarter. Yet with the share price around ¥6,614 after the release, the immediate reaction appears more muted than...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By